# Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors

> **NCT04262466** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Immunocore Ltd** · enrollment: 410 (actual)

## Conditions studied

- Select Advanced Solid Tumors

## Interventions

- **DRUG:** Brenetafusp
- **DRUG:** Brenetafusp and pembrolizumab
- **DRUG:** Brenetafusp and chemotherapy
- **DRUG:** Brenetafusp and monoclonal antibodies and chemotherapy
- **DRUG:** Brenetafusp and tebentafusp
- **DRUG:** Brenetafusp and bevacizumab
- **DRUG:** Brenetafusp and kinase inhibitors

## Key facts

- **NCT ID:** NCT04262466
- **Lead sponsor:** Immunocore Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-02-25
- **Primary completion:** 2026-10
- **Final completion:** 2027-12
- **Target enrollment:** 410 (ACTUAL)
- **Last updated:** 2026-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04262466

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04262466, "Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT04262466. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*